Denali Therapeutics Inc (DNLI) Implied Volatility Current

Tracking DNLI implied volatility helps you identify when options premiums on Denali Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Denali Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when DNLI IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Denali Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For DNLI, tracking metrics like DNLI IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on DNLI signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.

It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where DNLI implied volatility sits today versus where it has been. Our scanner ranks Denali Therapeutics Inc implied volatility against its historical range, surfaces extremes in DNLI IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Denali Therapeutics Inc IV is rich or cheap — measure it, then act on it.